Published in Health Business Week, April 13th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Aastrom Biosciences.
Report 1: Aastrom Biosciences, Inc., (ASTM), a company focused on the use of autologous cells for regenerative medicine, announced that the company's proprietary Tissue Repair Cells (TRCs) received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of dilated cardiomyopathy (DCM), a severe chronic disease of the heart.
In the U.S., Orphan Drug Designation provides a variety of incentives,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.